The Latest Cardiac and Vascular News
WASHINGTON, July 18, 2024 /PRNewswire/ — The Heart Failure Society of America (HFSA) recently announced the selection of new officers and board members for the society with terms starting at the conclusion of the HFSA Annual Scientific Meeting 2024 (ASM), which will take place September…
ROCKVILLE, Md., June 7, 2023 /PRNewswire/ — The Heart Failure Society of America (HFSA) today announced the first cohort of heart failure (HF) providers to earn the Heart Failure Certification (HF-Cert). The multi-disciplinary certification recognizes HF providers who have demonstrated advanced-level knowledge and skill to provide competent heart failure services in the United States. Seventy-eight candidates who took […]
ROCKVILLE, Md., Feb. 6, 2023 /PRNewswire/ — A new joint guideline published today by the Heart Failure Society of America (HFSA) and the International Society for Heart and Lung Transplantation (ISHLT) addresses the growing availability and use of acute or temporary mechanical support devices. The joint guideline provides critical recommendations and protocols for the management of patients requiring acute […]
Oak Ridge, TN, Jan. 19, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces joining the Heart Failure Society of America (HFSA) as a corporate member to collaborate and deepen engagement with leaders in the field of heart failure. “The HFSA is the premier society focused on improving Heart […]
Clinical Leadership and Management Call Scheduled for Wednesday, October 5, 2022, at 8:55am Eastern Time SUNNYVALE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its FDA designated Breakthrough CardiAMP® Cell Therapy for Heart Failure pivotal trial […]
Statistically Significant Reduction in CV Mortality and HF Rehospitalizations as Compared to IV Diuretics at 30 and 90 Days MINNEAPOLIS, Oct. 03, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the results of the AVOID-HF clinical study analysis presented at […]
CARLSBAD, Calif. and BRISBANE, Australia, Sept. 30, 2022 /PRNewswire/ — ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to maximize patient health, today announced two poster presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, which is taking place Sept. 30 to Oct. 3 in Washington D.C. The posters are […]
— Pediatric efficacy data for both patients show initial improvements across clinical, functional and biomarker endpoints with six to nine months of follow-up; positive results including protein expression obtained at three and six months consistent with adult cohorts at similar timeframe— — Results demonstrate sustained clinical benefit across all parameters in adult patients with up to 36 […]
ROCKVILLE, Md. , May 17, 2022 /PRNewswire/ — A new position paper published today by the Heart Failure Society of America (HFSA) outlines disparities in healthcare that affect patients with heart failure, including race and ethnicity, socioeconomic factors, and social determinants of health. The statement also presents actions that can be taken to address those disparities at the […]
PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced partnerships with the Dilated Cardiomyopathy (DCM) Foundation, the Heart Failure Society of America (HFSA) and the American Association of Heart Failure Nurses (AAHFN). The company […]
